Navigation Links
European Commission's Joint Research Centre's annual report 2010
Date:5/6/2011

This report provides an overview of the activities, accomplishments and resources related to the JRC's work carried out during 2010 and includes figures on staff, budget and publications.

In her foreword, Commissioner Mire Geoghegan-Quinn, in charge of research, innovation and science, highlights the need for policy making based on the best possible advice and affirms that "the JRC has built an excellent reputation as a world-class provider of scientific and technical support to European policy makers and legislators". The Commissioner refers as well to the role of the JRC as a "trusted and truly independent voice advising us on what is on the horizon in order to take timely policy decisions".

JRC Director-General, Dominique Ristori, emphasizes JRC efforts to support the Europe 2020 policy priorities addressing major challenges such as health, safety and security.

Examples of JRC's results throughout the year are described, such as the European-wide electricity grid model, contributions to the car emissions regulations, the crisis response work to Haiti and the methods to measure mycotoxins in infant food.

Many other highlights of JRC's work in different areas, such as energy (including nuclear), safety of food and consumer products, open and competitive economy or sustainable management of natural resources can also be found in the report.

In addition, an overview is given of the JRC mission and its implementation, the scientific activities and relations with the outside world. It covers as well the JRC input to the various stages of the policy cycle: from anticipation and formulation to policy adoption, implementation and evaluation.


'/>"/>

Contact: Elena Gonzalez Verdesoto
elena.gonzalez-verdesoto@ec.europa.eu
322-299-9862
European Commission Joint Research Centre
Source:Eurekalert

Page: 1

Related biology technology :

1. Cyberonics Announces First Implant of AspireSR™ Seizure Response Product in European Trial
2. Saladax Biomedical, Inc. Announces European Commercialization Team
3. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
4. European Commission Approves DuPont Tender Offer to Acquire Danisco
5. Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
8. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
9. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
10. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
11. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):